SecBot SecBot

PTHS

Pelthos Therapeutics Inc.
NYSE· Biological Products, (No Diagnostic Substances)· Inc. NV· CIK 0001919246 Biotech & Drug Discovery
$17.34 +0.34 (+2.00%)
Oct 26 4:00 PM ET · prev $17.00
Market cap
$75.0M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$50.00
+188% · range $40.00–64.00
Next earnings
Nov 12
in 17 days
1 year
−45.8%
from $32.00 · Oct 27
30 days
−18.4%
from $21.25
52-week range
$17.00–37.42
−54% from high · low Oct 23
Avg volume 20D
50.4K
shares / day
Short interest
104.6K
≈2.7% of shares · +11.6%
Days to cover
4.1
at average volume
Insider net
+$794.0K
1 buyer · 5 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH Pelthos Therapeutics reported Q2 2026 revenue of $15.4M (up 45% QoQ) driven by strong Zelsuvmi prescription…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $1000.0K at an average $27.82. 5 insiders sold $206.0K. Price is 38% below their cost.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +11.6% to 104.6K shares. 4.1 days to cover, ≈2.7% of shares.

  • TrendDOWNTREND

    22% below its 50-day average. New closing low $17.00 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED2,217$62.7K
UBS Group AGADD764$16.1K
GEODE CAPITAL MANAGEMENT, LLCADD13,625$422.4K
UBS Group AGDOUBLED434$13.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy9Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +188%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026Lake Street
MAINTAIN
MAINTAINBuy
Aug 14, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
May 15, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$1000.0K
bought · 1 insider
$206.0K
sold · 5 insiders
−37.7%
vs their $27.82 cost
DateInsiderTypeValue
Oct 2, 2026
Friedberg Ezra M
Director
SELL$11.6K
Oct 2, 2026
Greenleaf Peter
Director
SELL$16.9K
Oct 2, 2026
Pauls Matthew
Director
SELL$16.5K
Jul 2, 2026
Friedberg Ezra M
Director
SELL$655.81
Jul 2, 2026
Friedberg Ezra M
Director
SELL$13.9K
Jul 2, 2026
Pauls Matthew
Director
SELL$18.0K
Jul 2, 2026
Pauls Matthew
Director
SELL$2.6K
Jul 2, 2026
Greenleaf Peter
Director
SELL$2.3K

Earnings setup

Estimates
Nov 12
reports in 17 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY-$5.14-$7.76–-$1.45+9.6%$110.3M

Short side

FINRA· Sep 30, 2026
104,573
shares short
+11.6%
vs prior settlement
4.1
days to cover
≈2.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 Insider
Friedberg Ezra M sold 558 shares
Director @ $20.72 ($11.6K)
Oct 2, 2026 Insider
Greenleaf Peter sold 797 shares
Director @ $21.17 ($16.9K)
Oct 2, 2026 Insider
Pauls Matthew sold 786 shares
Director @ $21.00 ($16.5K)
Oct 1, 2026 SEC
Pelthos Therapeutics held its 2026 Annual Meeting on September 29, 2026, where stockholders approved the new 2026…
8-K — Impact 2/10
Aug 13, 2026 SEC
Pelthos Therapeutics reported Q2 2026 revenue of $15.4M (up 45% QoQ) driven by strong Zelsuvmi prescription growth…
8-K — Impact 6/10
Aug 13, 2026 Earnings calendar
PTHS Q2 2026 Earnings Scheduled — 2026-08-13
Aug 3, 2026 SEC
Pelthos Therapeutics, Inc. announced it will report its Q2 2026 results on August 13, 2026.
PRESS-RELEASE — Impact 1/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
2,217 shares ($62.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
PTHS Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Aug 13, 2026
Earnings date
PTHS Q2 2026 Earnings Scheduled — 2026-08-13
Aug 3, 2026
Earnings
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Company to hold a conference call at 8:30 a.m. ET Company to hold a conference call at 8:30 a.m. ET
Jul 24, 2026
Company news
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it…
Jun 30, 2026
Press release
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to…
May 28, 2026
Press release
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to…

SecBot reports

10 filings · 2 press releases · 1 bullish · 2 bearish · 7 neutral
All PTHS filing & press-release reports (12)